Mechanisms of Resistance and Relapse After CAR-T Cell Therapy

Mehmet Emrah Selli, Prarthana Dalal, Sattva S. Neelapu, Nathan Singh

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations


Chimeric antigen receptor (CAR)-engineered T cells can mediate impressive responses in a subset of patients with B cell malignancies. Clinical trial and real-world data, however, reveal that most patients will not achieve durable remission. Therapeutic failure appears to segregate into two distinct models: inherent resistance, in which there is no meaningful disease response after treatment, or acquired resistance, in which disease recurrence follows a transient response. A host of studies have identified that both forms of failure can result from tumor-intrinsic evasion mechanisms which can be antigen-dependent or independent. Alternatively, resistance or relapse can occur due to T cell dysfunction, both intrinsic to the cells prior to infusion or that develops after delivery to patients. In this chapter, we review the mechanistic and correlative studies investigating resistance to CAR-T cells, and discuss strategies designed to overcome this significant hurdle to the broader success of this therapy.

Original languageEnglish
Title of host publicationCancer Drug Discovery and Development
PublisherHumana Press Inc.
Number of pages13
StatePublished - 2022

Publication series

NameCancer Drug Discovery and Development
ISSN (Print)2196-9906
ISSN (Electronic)2196-9914


  • Alternative splicing
  • Antigen escape
  • Antigen masking
  • BCMA
  • CD19
  • CD22
  • Chimeric antigen receptor
  • Exhaustion
  • Resistance
  • T cell dysfunction
  • T cell fitness
  • Trogocytosis


Dive into the research topics of 'Mechanisms of Resistance and Relapse After CAR-T Cell Therapy'. Together they form a unique fingerprint.

Cite this